---

Journal of Applied Nonlinear Dynamics 12(4) (2023) 631--659 | DOI:10.5890/JAND.2023.12.002

Koyel Chakravarty

Department of Mathematics, School of Engineering and Applied Sciences, SRM University AP, Andhra Pradesh

- 522240, India

Download Full Text PDF

 

Abstract

Despite stupendous advancement of medical science, yet mankind gets perplexed when it comes to cancer. As yet cancer poses substantial threat to life as it is lethal in some cases due to its complexity and heterogeneity. With the objective of increasing the potency of cancer treatment, scientists are now focussing on combination therapy such as chemovirotherapy. In the current study, an updated and realistic mathematical model embracing different facets like uninfected tumour cells, infected tumour cells, free virus particles, chemotherapeutic agent, tumour specific immune cells and virus specific immune cells is advocated. In addition to mutual interactions between cells, diffusion phenomenon plays a vibrant role on account of their mobility. All these biological and physical processes are embodied in the novel mathematical model. Stability analysis corresponding to the temporal system along with its sub-models undergoing comparative study is performed. Suitable numerical methods are adopted for the model outcome followed by their exhaustive delineations. Spatial distributions are visualized using graphical manifestations. Sensitized parametric variation is illustrated pictorially. The study concludes that with proper management of model parameters so that cancerous tumours can be eradicated from the body using chemovirotherapy effectively.

Acknowledgments

The author is highly grateful to the anonymous reviewers for their valuable comments and suggestions.

References

1. [1]	Binz, E. and Lauer, U. (2015), Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy, Oncolytic Virotherapy, 4, 39-48.

2. [2]	Mokhtari, R.B., Homayouni, T.S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., and Yeger, H. (2017), Combination therapy in combating cancer. Oncotarget, 8(23), 38022-38043.

3. [3]	Blagosklonny, M.V. (2005), Overcoming limitations of natural anticancer drugs by combining with artificial agents, Trends in Pharmacological Sciences, 26(2), 77-81.

4. [4]	Ottolino, P., Diallo, J.S., Lichty, B.D., Bell, J.C., and McCart, J.A. (2010), Intelligent design: combination therapy with oncolytic viruses, Molecular Therapy, 18(2), 251-263.

5. [5]	Bartkowski, M.J., Bridges, S., Came, P., and et al (2012), Chemotherapy of Viral Infections. P. E. Came and L. A. Caliguiri, Eds. Vol.61.

6. [6]	Ungerechts, G., Frenzke, M., Yaiw, K., Miest, T., Johnston, P., and Cattaneo, R. (2010), Mantle cell lymphoma salvage regimen: Synergy between a reprogrammed oncolytic virus and two chemotherapeutics, Gene therapy, 17(12), 1506-1516.

7. [7]	Ulasov, I., Sonabend, A., Nandi, S., Khramtsov, A., Han, Y., and Lesniak, M. (2009), Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo, British Journal of Cancer, 100, 1154-1164.

8. [8]	Alonso, M., Gomez-Manzano, C., Jiang, H., Bekele, N., Piao, Y., Yung, W., Alemany, R., and Fueyo, J. (2007), Combination of the oncolytic adenovirus icovir-5 with chemotherapy provides enhanced anti-glioma effect in vivo, Cancer Gene Therapy, 14, 756-761.

9. [9]	Cody, J. and Hurst, D. (2015), Promising oncolytic agents for metastatic breast cancer treatment, Oncolytic Virother, 4, 63-73.

10. [10]	Gomez-Gutierrez, J., Nitz, J., Sharma, R., Wechman, S., Riedinger, E., Martinez-Jaramillo, E., Zhou, H., and McMasters, K. (2016), Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo, Virology, 487, 249-259.

11. [11]	Nguyen, A., Ho, L., and Wan, Y. (2014), Chemotherapy and oncolytic virotherapy: Advanced tactics in the war against cancer, Frontiers in Oncology, 4, 1-10.

12. [12]	Wodarz, D. and Komarova, N. (2014), Dynamics of Cancer: Mathematical Foundations of Oncology, World Scientific.

13. [13]	Tian, J. (2011), The replicability of oncolytic virus: defining conditions in tumor virotherapy, Mathematical Biosciences and Engineering, 8, 841–860.

14. [14]	Usher, J.R. (1994), Some mathematical models for cancer chemotherapy, Journal of Computers $\&$ Mathematics with Applications, 28, 73-80.

15. [15]	Malinzi, J., Eladdadi, A., and Sibanda, P. (2017), Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment, Journal of Biological Dynamics, 11, 244-274.

16. [16]	Malinzi, J., Ouifki, R., Eladdadi, A., Torres, D.F.M., and White, K.A.J. (2018), Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis. Mathematical Biosciences and Engineering, 15(6), 1435-1463.

17. [17]	Malinzi, J. (2019), Mathematical analysis of a mathematical model of chemovirotherapy: Effect of drug infusion method, Computational and Mathematical Methods in Medicine, https://doi.org/10.1155/2019/7576591.

18. [18]	Geng, C., Paganetti, H., and Grassberger, C. (2017), Prediction of treatment response for combined chemo- and radiation therapy for non-small cell lung cancer patients using a bio-mathematical model, Scientific Reports, 7, 13542.

19. [19]	Lopez, A., Iarosz, K., Batista, A., Seoane, J., Viana, R., and Sanjuan, M. (2019), The role of dose density in combination cancer chemotherapy, Communications in Nonlinear Science and Numerical Simulation, 79, 104918.

20. [20]	Bashkirtseva, I. and Ryashko, L. (2020), Tumor stabilization induced by t-cell recruitment fluctuations, International Journal of Bifurcation and Chaos, 30(12), 2050179.

21. [21]	Bashkirtseva, I. and Ryashko, L. (2020), Analysis of noise-induced phenomena in the nonlinear tumor–immune system, Physica A, 549, 123923.

22. [22]	Bashkirtseva, I., Ryashko, L., Duarte, J., Seoane, J., and Sanjuan, M. (2021), The role of noise in the tumor dynamics under chemotherapy treatment, The European Physical Journal Plus, 136(11), 1123-1135.

23. [23]	Prigogine, I. and Lefever, R. (1980), Stability problems in cancer growth and nucleation. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 67, 389-393.

24. [24]	Spratt, J.S., Meyer, J.S., and Spratt, J.A. (1996), Rates of growthof humanneoplasms:part I, Journal of Surgical Oncology, 61, 68-83.

25. [25]	Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J., Hlatky, L., and Hahnfeldt, P. (2014), Classical mathematical models for description and prediction of experimental tumor growth, Plos Computational Biology, 10, e1003800.

26. [26]	Pinho, S., Rodrigues, D., and Mancera, P. (2011), A mathematical model of chemotherapy response to tumour growth, Canadian Applied Mathematics Quarterly, 19, 369-384.

27. [27]	Aghi, M., Rabkin, S., and Martuza, R.L. (2006), Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication, Journal of the National Cancer, 98, 38-50.

28. [28]	Bosl, G. and Patil, S. (2011), Carboplatin in clinical stage I seminoma: Too much and too little at the same time, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(8), 949-952.

29. [29]

    Oliver, R., Mead, G., Rustin, G., Joffe, J., Aass, N., Coleman, R., Gabe, R., Pollock, P., and Stenning, S. (2011), Randomized trial of carboplatin versus radiotherapy for stage I seminoma: Mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214), Journal of Clinical Oncology, 29(8), 957-962.

30. [30]	Kirschner, D. and Panetta, J. (1998), Modeling immunotherapy of the tumor–immune interaction, Journal of Mathematical Biology, 37, 235-252.

31. [31]	Bajzer, \u{Z}., Carr, T., Josić, K., Russell, S., and Dingli, D. (2008), Modeling of cancer virotherapy with recombinant measles viruses, Journal of theoretical Biology, 252(1), 2008.

32. [32]	Brock, T. (1990), The Emergence of Bacterial Genetics, Cold Spring Harbor Laboratory Press.

33. [33]	Ribba, B., Marron, K., Agur, Z., Alarcon, T., and Maini, P. (2005), A mathematical model of doxorubicin treatment efficacy for non-hodgkin's lymphoma: Investigation of the current protocol through theoretical modelling results, Bulletin of Mathematical Biology, 67, 79-99.

34. [34]	Nise, N.S. (2011), Control System Engineering, John Wiley \& Sons.

35. [35]	Mahasa, K., Eladdadi, A., Pillis, L., and Ouifki, R. (2017), Oncolytic potency and reduced tumorspecificity in oncolytic virotherapy, a mathematical modelling approach, Plos One, 12(9), e0184347.

36. [36]	Eftimie, R., Dushoff, J., Bridle, B., Bramson, J.L., and Earn, D. (2011), Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions, Bulletin of Mathematical Biology, 73(12), 2932-2961.

37. [37]	Okamoto, K., Amarasekare, P., and Petty, I. (2014), Modeling oncolytic virotherapy: Is complete tumor-tropism too much of a good thing? Journal of Theoretical Biology, 358, 166-178.

38. [38]	Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000), Tumor vascular permeability and the EPR effect inmacromolecular therapeutics: A review, Journal of Controlled Release, 65(1-2), 271-284.